(Reuters) – Becton Dickinson & Co. (NYSE:BDX) reported better-than-expected full-year profits and revenue, helped by strong sales in its diabetes care and drug-delivery businesses.

Becton said it expected adjusted earnings from continuing operations to be between $6.76 and $6.83 per share for the year ending September 2015.

Analysts on average were expecting $6.70 per share, according to Thomson Reuters I/B/E/S.

Becton, which makes products such as disposable needles, syringes and catheters to administer drugs, last month said it would buy CareFusion (NYSE:CFN), whose products include infusion pumps, to create a market leader in the $20 billion medication management industry.

Becton said it expected revenue to rise 4.5-5% on a foreign currency neutral basis for the year ending Sept. 30, 2015. The company reported revenue of $8.45 billion this year.

Net income rose 230.8% to $301 million, or $1.53 per share, in the 4th quarter, from $91 million, or 46¢ per share, a year earlier.

The year-ago quarter included pretax charges of $347 million. On an adjusted basis, the company earned $1.68 per share, exceeding the average analyst estimate of $1.65.

Revenue rose 4.8% to $2.20 billion, above analysts’ average estimate of $2.16 billion.

BDX shares were up 2.0% to $130 even in pre-market trading this morning.